Press Releases

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog named MIRA1a, will participate in the 6th Annual Cannabinoid-Derived Drug Development Summit taking place September 11-13, 2023 in Boston, MA. Dr. Adam Kaplin, President and Chief Scientific Officer of MIRA Pharmaceuticals, will be featured as a keynote speaker during the

Tvardi Therapeutics, Inc., a privately held biopharmaceutical company in the clinical stage, with a focus on developing STAT3 inhibitors, has initiated a significant phase in its ongoing REVERTIPF trial. This clinical trial marks the dosing of the first patients. The REVERTIPF trial is designed as a 12-week, randomized, double-blind study aimed at assessing both safety and clinical effectiveness of TTI-101, a STAT3 inhibitor, at three varying doses. This evaluation is conducted either on its

MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announced today an agreement under which Huadong has been granted exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to develop and commercialize MC2’s drug, Wynzora® Cream for the treatment of plaque psoriasis. U

Pfizer Inc. and BioNTech SE today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has also recommended the updated vaccine for children 6 months th

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia. Research Instruments (“Everlif

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces that a new U.S. patent which covers CAMCEVI® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as "the Orange Book". On August 8, 2023, the United States Patent and Trademark Office (USPTO) issued U.S. patent No. 11,717,555 B2, under the title &

Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada. Propranolol LA is a generic equivalent of Inderal® LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA's launch caters to the needs of Canadian patients,reaffirming Lupin's commitment to enhancing

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan’s 2023 Global Customer Value Leadership Award in the aseptic fill-and-finish market for the company’s high performance for its customers. The award, presented annually by the international growth strategy consulting firm, focuses on both business and customer impact along with industry status and trends in the market. In previous years the CDMO was awarded

LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated statins and other oral lipid lowering agents, announced the results of the LIBerate-HeFH trial. The results from the large global Phase 3 randomized, place

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023. This represents a decrease from RM6.33 million in the corresponding quarter of the preceding year, owing to a deliberate pivot from vaccines to cell and gene therapy products, focusing more on genetic screening initiatives. For the quarter under review, the Group recorded a loss before tax (LBT) of RM9.98 million